| abstract |
The present invention relates to a compound of formula I n nwhereinn Ar, R 1 , R 2 , R 3 , n, and o are as defined hereinn nor to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). |